Nano Dimension Ltd. (NNDM) Earnings Call Transcripts
Nano Dimension Ltd.'s Latest Earnings Call - June 15, 2026
In the June 15, 2026 earnings call, Nano Dimension Ltd. announced a nonbinding term sheet for a proposed business combination with Infinite Epigenetics, marking a strategic shift towards AI-powered preventive health and diagnostics. This move is aimed at leveraging Nano's capital base and public listing to accelerate Infinite's growth in a large and growing addressable market. While specific revenue and earnings figures were not disclosed, management emphasized the potential for significant value creation for shareholders, with a proposed structure allowing existing Nano shareholders to retain a minority interest in the combined entity, which is expected to trade under the ticker IEAI.
Reported metrics
| Metric | Value |
|---|---|
| Ownership Structure | Meaningful minority interest (positive) |
| Market Opportunity | $90 billion (positive) |
| Premium Valuation | 20% (positive) |
| Sample Collection | 120,000 (positive) |
| Revenue Generation | Existing revenue-generating operations (positive) |
| Cash Flow Guidance | Positive cash flow (neutral) |
Guidance from management
Management indicated that the combined company would focus on accelerating growth and expanding its commercial reach while aiming for positive cash flow without the need for additional capital raises.
What analysts pressed on
Analysts expressed concerns regarding the integration of Infinite's operations and the execution of the growth strategy post-combination. There were questions about how the proposed combination would impact Nano's existing product lines and overall operational focus during the transition period.
Main topics on the call
- Proposed Business Combination — Nano Dimension has entered into a nonbinding term sheet for a business combination with Infinite Epigenetics, which is described as 'a market-moving platform that is commercially available today.' This strategic move is ...
- Strategic Rationale — Management highlighted the rigorous process of evaluating over 20 potential opportunities, concluding that Infinite Epigenetics 'clearly stood above the rest' due to its proven technology and revenue-generating operation...
- Market Opportunity — The combined company is expected to target a $90 billion U.S. clinical diagnostics market, focusing on chronic diseases such as cardiovascular disease and type 2 diabetes. Management stated, 'the opportunity in front of ...
- Shareholder Value — Existing Nano shareholders are expected to retain a meaningful minority ownership interest in the combined company, with a valuation reflecting a '20% premium to Nano's estimated net cash at closing.' This structure aims...
Read the full Nano Dimension Ltd. transcript (June 15, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Nano Dimension Ltd.
Nano Dimension Ltd. (NNDM) is a publicly listed company in the Machinery industry, within the Industrials sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 32 calls on record spanning May 14, 2020 to June 15, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 32 Nano Dimension Ltd. earnings call transcripts on record, spanning May 14, 2020 to June 15, 2026. Based on this history, Nano Dimension Ltd. reports quarterly. The most recent call on file is dated June 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- NNDM
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Industrials
- Industry
- Machinery
- Calls on record
- 32
- First call
- May 14, 2020
- Most recent
- June 15, 2026
- Reporting cadence
- quarterly